Advanced Malignancies | Norton Healthcare

Indication: Advanced Malignancies

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination with AB122 in Participants with Advanced Malignancies

Sub-indication: Miscellaneous Malignancies

Study Type: Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Arcus Biosciences, Inc.

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.